MIR628: A Potential Drug Target and Biomarker (G693213)

MIR628: A Potential Drug Target and Biomarker

Molecular Targets in Cancer

Molecular targets are important areas of research in cancer treatment, as they can provide insights into the underlying mechanisms of cancer development and progression. One such target that has gained significant attention in recent years is MIR628, a gene that has been identified as a potential drug target in cancer.

In cancer, the regulation of mitochondrial function is disrupted, leading to an imbalance in energy production that promotes cell proliferation and survival. MIR628 is a non-coding RNA molecule that has been shown to play a critical role in regulating mitochondrial function. It is expressed in a variety of tissues and cells, including cancer cells, and has been shown to be involved in cell survival, metabolism, and apoptosis.

MIR628 as a drug target

The potential drug target for MIR628 is based on its role in regulating mitochondrial function and its expression in cancer cells. MIR628 has been shown to promote the growth and survival of cancer cells in cell culture and animal models. By inhibiting MIR628 function, researchers have found that they can significantly reduce the growth and survival of cancer cells.

One approach to targeting MIR628 is to use small molecules, such as drugs that inhibit the activity of MIR628 enzymes or modulate its expression levels. Another approach is to use RNA interference (RNAi) technology to knockdown MIR628 in cancer cells. RNAi has been shown to be an effective way to reduce the expression of genes in cancer cells, including MIR628.

MIR628 as a biomarker

In addition to its potential as a drug target, MIR628 has also been identified as a potential biomarker for cancer. The expression of MIR628 has been shown to be elevated in a variety of cancer types, including breast, lung, and colorectal cancers. This suggests that MIR628 may be a useful biomarker for cancer diagnosis and monitoring.

One approach to using MIR628 as a biomarker is to measure its expression levels in cancer cells or tissue samples using techniques such as qRT-PCR or western blotting. This can provide information about the levels of MIR628 in the cancer cells and help researchers determine if it is a reliable biomarker for cancer diagnosis or monitoring.

Another approach to using MIR628 as a biomarker is to use it as a target for liquid biopsy, a technique that allows researchers to detect cancer cells in a patient's blood using a small sample of their tissue. This approach has the potential to improve the accuracy of cancer diagnosis, as it allows doctors to detect cancer at an early stage when it is most treatable.

Conclusion

MIR628 is a non-coding RNA molecule that has been shown to play a critical role in regulating mitochondrial function and its expression in cancer cells. The potential drug target for MIR628 is based on its role in promoting the growth and survival of cancer cells, and the use of small molecules or RNA interference technology to inhibit its function.

MIR628 has also been identified as a potential biomarker for cancer, with increased expression in a variety of cancer types. The use of MIR628 as a biomarker may have implications for cancer diagnosis and monitoring, as well as for the development of new cancer therapies. Further research is needed to fully understand the role of MIR628 in cancer biology and its potential as a drug target and biomarker.

Protein Name: MicroRNA 628

The "MIR628 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR628 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR629 | MIR630 | MIR631 | MIR632 | MIR633 | MIR634 | MIR635 | MIR636 | MIR637 | MIR638 | MIR639 | MIR640 | MIR641 | MIR642A | MIR642B | MIR643 | MIR644A | MIR645 | MIR646 | MIR646HG | MIR647 | MIR648 | MIR649 | MIR6499 | MIR650 | MIR6500 | MIR6501 | MIR6502 | MIR6503 | MIR6504 | MIR6505 | MIR6506 | MIR6507 | MIR6508 | MIR6509 | MIR651 | MIR6510 | MIR6511A1 | MIR6511A2 | MIR6511A3 | MIR6511A4 | MIR6511B1 | MIR6511B2 | MIR6512 | MIR6513 | MIR6514 | MIR6515 | MIR6516 | MIR652 | MIR653 | MIR654 | MIR655 | MIR656 | MIR657 | MIR658 | MIR659 | MIR660 | MIR661 | MIR662 | MIR663A | MIR663AHG | MIR663B | MIR664A | MIR664B | MIR665 | MIR668 | MIR670 | MIR671 | MIR6715A | MIR6715B | MIR6716 | MIR6717 | MIR6718 | MIR6719 | MIR6720 | MIR6721 | MIR6722 | MIR6724-1 | MIR6726 | MIR6727 | MIR6728 | MIR6729 | MIR6730 | MIR6731 | MIR6732 | MIR6733 | MIR6734 | MIR6735 | MIR6736 | MIR6737 | MIR6738 | MIR6739 | MIR6740 | MIR6741 | MIR6742 | MIR6743 | MIR6744 | MIR6746 | MIR6747 | MIR6748